SpectraMax i3 Multi-Mode Detection System
See how you can do more with your microplate reader than you ever imagined.
Watch Video
Bioanalysis of Oxytocin
Ultrasensitive Quantification Assay for Oxytocin in Human Plasma Using an LC/MS Microfluidics Platform
Watch Video

The Discoverome, creative destruction of barriers for faster to patient medicines R&D

By Chris Molloy
Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.

Pharma Derisking, approaches to reduce liability to major metabolically-driven causes of drug attrition

By Guy Webber
Intelligent application of early in vitro testing can help mitigate major drug development risks.

Spheroids rapidly becoming a preferred 3D culture format

By Dr John Comley
There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture.

Something old, something new... a marriage of technologies for immuno-oncology in vivo studies

By Dr Philip Dube
Discovering & validating novel therapeutic targets to add to the immuno-oncology arsenal requires refined preclinical models that meet needs for suitability, scalability & clinical relevancy throughout the phases of target discovery & drug validation.

Three-dimensional cell culture: a rapidly emerging technique for drug discovery

By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen
Past decades have witnessed significant efforts toward the development of 3D cell cultures. They are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.

Immuno-Oncology's Biomarker Dilemma How to add value in an uncertain development landscape

By Dr Rachel Laing and Olivier Lesueur
Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies.

Monitoring the balance between immune repression and stimulation in cancer immunotherapy

By Dr Peter Schulz-Knappe and Dr Georg Lautscham
Cancer remains one of the main causes of death worldwide, yet recent strides have been made in the form of new cancer immunotherapies.

Propath Receives Queen's Award for Enterprise

The Prime Minister's office has announced that Propath is to receive a Queen's Award for Enterprise in recognition of the company's exceptional contribution to the UK's Life Sciences sector.

New microplate-based method to measure OCR and ECA under steady-state (O2)

Cayman Chemical, in collaboration with BMG LABTECH GmbH, has developed a novel assay kit to measure mitochondrial function under a dynamic range of oxygen concentrations.

Gyros Protein Technologies signs distribution agreement with Luxembourg Bio Technologies for peptide synthesis reagents

Gyros Protein Tech. has signed an exclusive distribution agreement with Luxembourg Bio Tech. for two of its proprietary coupling agents, PyOxim & K-Oxyma, & HDMA on a non-exclusive basis.

OGT's expanded NGS cancer panels enable sequencing of difficult genes

Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its SureSeq myPanel NGS Custom Cancer Panel content.

Enamine to Collaborate with EMBL for Cancer Drug Discovery Research

Enamine will provide library synthesis, medicinal chemistry and biological services for the discovery and development of novel small molecules against EMBL's proprietary anti-cancer targets.

Top three global diagnostics company takes exclusive rights to several of Avacta's Affimer reagents

Avacta have reported that an evaluation of Affimer technology concluded successfully & that a third party has taken exclusive rights to several Affimer reagents for an undisclosed sum.